Methods of treating cell proliferative disorders
View Patent ↗The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis.
1. A method of treating a cell proliferative disorder, comprising: administering to a subject in need thereof a compound having the structure
or a salt thereof, wherein R p is selected from —CH 2 —O—P(O)(OH) 2 , —CH 2 CH 2 —O—P(O)(OH) 2 and —CH 2 OH, in an amount effective to treat the cell proliferative disorder wherein the cell proliferative disorder is selected from B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone B-cell lymphoma, hairy cell leukemia, plasma cell myeloma/plasmacytoma, extranodal marginal zone B-cell lymphoma of MALT type, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma, diffuse large B-cell lymphoma, mediastinal large B-cell lymphoma, primary effusion lymphoma, and Burkitt's lymphoma/Burkitt cell leukemia.
2. The method of claim 1 in which the cell proliferative disorder is follicular lymphoma.
3. The method of claim 1 in which the compound is of the formula:
or is a salt thereof.
4. The method of claim 3 in which the cell proliferative disorder is B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.
5. The method of claim 3 in which the cell proliferative disorder is B-cell prolymphocytic leukemia.
6. The method of claim 3 in which the cell proliferative disorder is lymphoplasmacytic lymphoma.
7. The method of claim 3 in which the cell proliferative disorder is splenic marginal zone B-cell lymphoma.
8. The method of claim 3 in which the cell proliferative disorder is hairy cell leukemia.
9. The method of claim 3 in which the cell proliferative disorder is plasma cell myeloma/plasmacytoma.
10. The method of claim 3 in which the cell proliferative disorder is extranodal marginal zone B-cell lymphoma of MALT type.
11. The method of claim 3 in which the cell proliferative disorder is nodal marginal zone B-cell lymphoma.
12. The method of claim 3 in which the cell proliferative disorder is mantle-cell lymphoma.
13. The method of claim 3 in which the cell proliferative disorder is diffuse large B-cell lymphoma.
14. The method of claim 3 in which the cell proliferative disorder is mediastinal large B-cell lymphoma.
15. The method of claim 3 in which the cell proliferative disorder is primary effusion lymphoma.
16. The method of claim 3 in which the cell proliferative disorder is Burkitt's lymphoma/Burkitt cell leukemia.
17. A method of treating a cell proliferative disorder, comprising:
administering to a subject in need thereof a compound having the structure
or a salt thereof, wherein the cell proliferative disorder comprises diffuse large B-cell lymphoma.
18. A method of treating a cell proliferative disorder, comprising:
administering to a subject in need thereof a compound having the structure
or a salt thereof, wherein the cell proliferative disorder comprises follicular lymphoma.